Cervarix

Global Vaccine Adjuvants Market Report (2022 to 2035) - by Type of Vaccine Adjuvant, Route of Administration, Target Therapeutic Area and Key Geographies - ResearchAndMarkets.com

Retrieved on: 
Monday, June 20, 2022
Pharmaceutical, Health, Medical Devices, Tetanus, Immunity, HIV-AIDS, Industry, Investor, Cough, Type, Administration, CpG, COVID-19, Cholera, Measles, Death, Vaccine, Public sector, 1018, Research, Antigen, USD, DNA, AS04, Diphtheria, Malaria, MF59, Cervarix, Zoster vaccine

The "The Vaccine Adjuvants Market by Type of Vaccine Adjuvant, Route of Administration, Target Therapeutic Area and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Vaccine Adjuvants Market by Type of Vaccine Adjuvant, Route of Administration, Target Therapeutic Area and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • This report features an extensive study of the current market landscape and future potential of the vaccine adjuvant market.
  • According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025.
  • Currently, more than 70 companies and academic / research institutes are engaged in the development of various types of vaccine adjuvants.

Cancer Vaccines Global Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 13, 2022
Pharmaceutical, Health, Oncology, Dendreon, Immunity, Technology, Medicine, DNA, Gardasil, Woman, COVID-19, WHO, Immunotherapy, Cervical cancer, Incidence, B cell, GSK, Acupuncture, Organization, Homeopathy, HPV, World, Merck, Lung, Growth, GlaxoSmithKline, Sanofi Pasteur, Vaccine, Immune system, Breast cancer, American Cancer Society, Antigen, Female, Yoga, Cervarix, CSL Limited, AstraZeneca, Acquisition, World Health Organization, Prostate, Pharmaceutical industry, Cancer, Bayer

The "Cancer Vaccines Global Market Report 2022: By Type, By Technology, By Cancer, By End-User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Vaccines Global Market Report 2022: By Type, By Technology, By Cancer, By End-User" report has been added to ResearchAndMarkets.com's offering.
  • The cancer vaccines market consists of sales of vaccines used for the treatment of cancers and related services by entities (organizations, sole traders and partnerships) that produce vaccines for cancer treatment.
  • The main types of cancer vaccines are preventive cancer vaccines and therapeutic cancer vaccines.
  • The different types of cancers include prostate, cervical, colorectal, throat, others and involves various technologies such as dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole cell cancer vaccines, viral vector & DNA cancer vaccines.

Virus-Like Particles (VLP's) Market Research Report 2021: Forecast to 2028 with COVID-19 Impact and Global Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 26, 2022
Infectious Diseases, Pharmaceutical, Health, COVID-19, Hepatitis, Food and Drug Administration, Coronavirus, Virus-like particle, PTM, Severe acute respiratory syndrome coronavirus, Therapy, Hepatitis C, HPV, HCV, Orthohantavirus, Government, RNA, Population, HBV, Cervarix, Chikungunya, VLP, FDA, Consistency, Virus, Hepatitis B, Growth, SARS, Incidence, Hepatitis B virus, Food, Hepatitis B Foundation, Mutation, Frontiers, A-DNA, Gaucher, Gaucher's disease, Safety, CAGR, DNA, Vaccine, Lassa mammarenavirus, Gardasil

The "Virus-like Particles (VLP's) Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Virus-like Particles (VLP's) Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.
  • However, the feasibility of VLPs as antigen carriers is questionable and complicated due to associated difficulties which is resulting in the sluggish growth of the global market.
  • The global virus-like particles (VLP's) market is segmented based on product type, source, and application.
  • Based on product type, the virus-like particles market is segmented as hepatitis, cancer/HPV, and Gaucher disease.

Global Human Papillomavirus (HPV) Vaccines Analysis Report 2021: Supplemental Approvals Boost Opdivo And Gardasil 9, But Limit Beovu

Retrieved on: 
Wednesday, February 17, 2021
Papillomavirus, Clinical medicine, Vaccination, Medicine, Vaccines, Cancer vaccines, Infectious causes of cancer, Cervarix, Gardasil, Human papillomavirus infection, Virus-like particle, HPV vaccine

DUBLIN, Feb. 17, 2021 /PRNewswire/ -- The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 17, 2021 /PRNewswire/ -- The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • There are currently three approved vaccines for HPV: Cervarix, Gardasil, and Gardasil 9.
  • Both vaccines are based on the recombinant expression of major capsid antigen L1 from different HPV serotypes, which self-assemble into virus-like particles (VLPs).
  • In 2014, Gardasil 9, a nine-valent vaccine capable of protecting from an additional 20% of HPV-related cancers, superseded Gardasil.

Icosavax Launches with $51 Million Series A Financing to Advance Computationally Designed VLP Vaccines

Retrieved on: 
Thursday, October 3, 2019
Other Health, University, Pharmaceutical, Education, General Health, Infectious diseases, Science, Biotechnology, Other Science, Research, Health, Vaccination, Drugs, Vaccines, Medicine, Papillomavirus, Cancer vaccines, RTT, Infectious causes of cancer, Cervarix, Gardasil, Virus-like particle, Vaccine

VLPs contain no genetic material, so they are non-infectious and can provide a safer alternative to live-attenuated or inactivated vaccines.

Key Points: 
  • VLPs contain no genetic material, so they are non-infectious and can provide a safer alternative to live-attenuated or inactivated vaccines.
  • Naturally occurring VLPs have delivered successful vaccines, including Gardasil and Cervarix against human papillomavirus (HPV) and Engerix-B and Recombivax HB against Hepatitis B.
  • Ralf developed and brought to licensure more than 25 different vaccines and has published extensively on vaccines and public health.
  • Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs.

PDS Biotechnology Prioritizes Development of PDS0101 in Advanced Cancers Following Promising Phase 1 Clinical Outcome Data

Retrieved on: 
Tuesday, October 1, 2019
Cancer, Infectious causes of cancer, Papillomavirus, RTT, Vaccines, Cervical intraepithelial neoplasia, Human papillomavirus infection, Intraepithelial neoplasia, Cervarix, HspE7

BERKELEY HEIGHTS, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotechnology) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of multi-functional immunotherapeutic products, today announced it will prioritize clinical development of PDS0101 in advanced cancers following its recent reporting of promising PDS0101 Phase 1 clinical trial outcome data.

Key Points: 
  • BERKELEY HEIGHTS, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotechnology) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of multi-functional immunotherapeutic products, today announced it will prioritize clinical development of PDS0101 in advanced cancers following its recent reporting of promising PDS0101 Phase 1 clinical trial outcome data.
  • On September 19, 2019, PDS reported clinical outcome data from a Phase 1 clinical trial of PDS0101 in patients with cervical intraepithelial neoplasia (CIN) infected with multiple high-risk, cancer-causing types of human papillomavirus (HPV).
  • Our intent is to continue to advance our previously announced combination studies with PDS0101 in various advanced HPV-associated cancers.
  • This approach has been recently supported by promising Phase 1 clinical outcome data, said Dr. Frank Bedu-Addo, CEO of PDS.

HPV Vaccine Market 2022 Demand, Key Players- Merck and Co., GlaxoSmithKline

Retrieved on: 
Wednesday, April 25, 2018
Cancer, Medicine, Papillomavirus, RTT, Vaccines, Infectious causes of cancer, HPV vaccines, Human papillomavirus infection, HPV-positive oropharyngeal cancer, Cervarix

Amongst the regions, North America accounts for the largest regional share in the global HPV vaccine market in 2017.

Key Points: 
  • Amongst the regions, North America accounts for the largest regional share in the global HPV vaccine market in 2017.
  • The report titled "Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) - By Region (North America, Europe, APAC and RoW), By Country (US, Canada, UK, Germany, France, China, India, Japan)" has covered and analysed the potential of Global HPV Vaccine Market and provides statistics and information on market size, shares and growth factors.
  • Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global HPV vaccine market.
  • Global HPV Vaccine Market (Actual Period: 2012-2016, Forecast Period: 2017-2022
    Regional Markets - North America, Europe, Asia-Pacific and Rest of the World (Actual Period: 2012-2016, Forecast Period: 2017-2022)